
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals has demonstrated a strong financial performance, generating $316 million in precision medicine revenue in the second half of 2025, with a notable 4% quarter-over-quarter growth attributed to successful sales in the U.S. The company’s promising pipeline, particularly with the potential expansion into prostate cancer diagnosis, could significantly increase the total addressable market by approximately $3.5 billion, providing substantial growth opportunities. Additionally, Telix's achievement of 2025 revenue targets underscores its effective execution and robust commercial performance, warranting a favorable outlook for the company’s stock.
Bears say
Telix Pharmaceuticals has reported a net loss of $1.0 million with an earnings per share (EPS) of $(0.30), surpassing both internal estimates and consensus but still indicating ongoing financial difficulties. The company faces multiple risks, including potential negative clinical results for its lead asset TLX591, delays in pipeline development, and regulatory challenges that may hinder its operations and revenue generation. Additionally, financial stability is threatened by balance sheet and liquidity risks, competition in the radiopharmaceutical market, and long-term dilution concerns, which collectively contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares